Literature DB >> 1954986

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis.

A Symeonidis1, A Kourakli, P Katevas, M Perraki, M Tiniakou, P Matsouka, V Georgoulias, N Zoumbos.   

Abstract

We determined nine immune function parameters at diagnosis in patients with myelodysplastic syndromes (MDS) and correlated the results with the FAB classification and prognosis by univariate and multivariate analyses. Patients with refractory anaemia (RA) and refractory anaemia with ring sideroblasts (RAS) tended to have a higher CD4/CD8 ratio and a lower amount of gamma-globulins and soluble interleukin-2 receptors in serum in comparison to those suffering from the other three subgroups of MDS. FAB classification, neutrophil and CD8+ T-cell number had the best discriminatory capacity for predicting survival less than 1 year, and FAB classification, neutrophil number and serum TNF levels were predictors for conversion to acute leukaemia. The frequent occurrence of infections, on the other hand, could be better predicted by the absolute numbers of neutrophils and CD4+ cells and by the skin test score.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954986     DOI: 10.1111/j.1600-0609.1991.tb01571.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  11 in total

1.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

2.  Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population.

Authors:  Dragomir Marisavljević; Nada Kraguljac; Zoran Rolović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Myelodysplastic Syndrome and Acute Lymphocytic Leukemia in Common Variable Immunodeficiency (CVID).

Authors:  Jennifer Toh; Rachel Eisenberg; Kamila Bakirhan; Amit Verma; Arye Rubinstein
Journal:  J Clin Immunol       Date:  2016-03-18       Impact factor: 8.317

Review 4.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

6.  The emerging role of lenalidomide in the management of lymphoid malignancies.

Authors:  Francisco J Hernandez-Ilizaliturri; Sameer A Batoo
Journal:  Ther Adv Hematol       Date:  2011-02

7.  Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.

Authors:  O Iwase; S Aizawa; Y Kuriyama; M Yaguchi; M Nakano; K Toyama
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

8.  Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.

Authors:  G Seipelt; A Ganser; H Duranceyk; A Maurer; O G Ottmann; D Hoelzer
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

Review 9.  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Authors:  Abdallah Abou Zahr; Ehab Saad Aldin; Rami S Komrokji; Amer M Zeidan
Journal:  J Blood Med       Date:  2014-12-22

Review 10.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.